Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

SCG to Start China/Singapore Trials of Cell Therapy for Hepatocellular Carcinoma

publication date: May 10, 2022

Singapore SCG Cell Therapy Pte has been approved to conduct China and Singapore trials of its autologous T-cell receptor T-cell therapy for hepatitis B virus related hepatocellular carcinoma (HCC), the most common form of liver cancer. SCG101 activates T-cells by recognizing the epitope of the hepatitis B virus surface antigen, which redirects T-cells against the HBV antigens. SCG develops novel immunotherapies for common infections and their cancers using T cell therapies, antibodies and therapeutic vaccines. Headquartered in Singapore, SCG also has operations in China and Germany. More details...

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital